Contracts › 75N93025C00034
75N93025C00034: To Develop a Lassa Fever Vaccine
Awarded to Medigen, Inc. by National Institutes of Health (NIH).
$4.5Mobligated
$4.5Mpotential value
25 August 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93025C00034 |
|---|---|
| Awardee | Medigen, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 27 |
| Period of performance | 23 September 2025 to 25 August 2028 |
| Potential end | 22 September 2030 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record